Skip to main content

FDA Approvals

FDA Approvals, Lymphoma

FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma

FDA Approvals, Lymphoma

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

FDA Approvals, Multiple Myeloma, Oncology

FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer

FDA Approvals, Leukemia, Oncology

Oral Onureg First Drug Approved for Adults with AML in Remission

Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions

Page 10 of 21
Results 91 - 100 of 205